资讯

The reemergence of myeloperoxidase-antineutrophil cytoplasmic antibodies — or MPO-ANCA — can serve ... remission in MPO-ANCA–positive ANCA-associated vasculitis, according to findings ...
The demographics and clinical data were retrieved after a review of the electronic health record. The type of cancer, ICI treatment, onset of vasculitis, ANCA type and treatment are summarised in ...
Background: Complement fragment C5a is strongly linked to the pathogenesis of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV). C5a receptor (C5aR), present on neutrophils, is a ...
Patients with AAV are associated with an increased risk for MI, particularly during the first 3 months after diagnosis.
CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic ...
"When I was in the hospital, I heard a lot about all the things I’d probably never be able to do again," says 18-year-old ...
WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company ...
Disagreements may arise due to differences in points of view, ideology or unhealthy competition that may yield either positive or negative consequences. While it's difficult to image that conflict ...
CD19-CAR T-cell treatment is a novel option of deep B cell depletion with promising results across different rheumatologic and musculoskeletal diseases (RMD). This and other cell-depleting approaches ...
The search strategy was developed by a medical librarian combining the terms false positive results, urine, and substance abuse testing and the generic names of 116 medications. When possible ...
The first of the selected abstracts came from Wolfgang Merkt, who presented an update on a patient who originally received third-generation CD19-CAR-T ...
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein(a) levels by more than 90% for at least six months with a single injection in a phase 2 trial, reinforcing its ...